looks like mmrf is turning the corner to the upside. shareholders will benefit while the people not in the game will leave with a wimper. Time is on our side !!!!
On 24 January 2013, orphan designation (EU/3/12/1097) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for lenalidomide for the treatment of follicular lymphoma.
Great for Celgene!!!
MMRF is not a love child.. No such thing as "loyalty" to a stock, a CEO, or a Company, especially a OTC, its an investment, and only good for a return of $$$$....Keep real JMHO